Apexigen uses antibodies derived from rabbits to develop therapies for diseases that are difficult to treat. LSIPR found out how it protects its novel technologies.
There’s no shortage of drugs formulated with antibodies derived from people or from mice. But California-based Apexigen has turned elsewhere, developing treatments with antibodies derived from rabbits.
Rituxan (rituximab) and Herceptin (trastuzumab) are just two examples of drugs that use antibodies derived from mice or humans, or humanised antibodies derived from mice. However, rabbits can generate a much broader diversity of antibodies for a target than a mouse, a human or many other species, says Mark Nevins, vice president of business development at Apexigen.
Using a process called gene conversion, rabbits’ immune systems can create antibodies that are generally of a higher quality, and have greater affinity, creating a stronger bond between the antibody and the antigen.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Apexigen, IP strategy, cancer, rabbit antibodies, APX005
